FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
00018607422022FYFALSEBausch & Lomb CorpP30DP1YP1YP6Mhttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp:/...
0001860742FALSEBausch & Lomb Corp00018607422022-11-022022-11-02UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM...
Fourth-Quarter 2022 Financial Results Revenues of $996 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $1 Million Adjusted...
Bausch & Lomb Corp 0001860742 false 0001860742 2023-02-14 2023-02-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Mr. Saunders Brings More Than 25 Years of Health Care Leadership to Bausch + Lomb Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or...
Campaign to Feature Personal Stories and Images from Bausch + Lomb SightMatters Community Members During Age-Related Macular Degeneration...
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live...
Acquisition Will Enhance Bausch + Lomb’s Surgical Portfolio with IC-8® Apthera™ Intraocular Lens Bausch + Lomb Corporation (NYSE/TSX: BLCO...
Enhanced Vitamin Includes the Same Clinically Proven AREDS 2 Formula with New Lutein and Zeaxanthin...
Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people...
Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live...
NOV03 is Being Investigated to Treat the Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction NOV03 PDUFA Action...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.